Early EU Approval Wins In Line For Daiichi/AZ & Lilly
Another Cancer Drug - Lumoxiti - Is Also On Track For Special Approval
Advanced breast cancer treatment Enhertu and non-small cell lung cancer and thyroid cancer therapy Retsevmo are set to win conditional marketing authorizations in the EU shortly. The two drugs are among a number of new products that the European Medicines Agency has just recommended for approval.
